Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCI699 in Primary Hyperaldosteronism
NCT00732771Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osilodrostat in primary hyperaldosteronism (PA), sponsored by Novartis. Started Jun 2008; status: completed.
02
Drugs
osilodrostat
03
Conditions
primary hyperaldosteronism (PA)
Beyond the preview
Go deeper on NCT00732771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00732771.